|
WO2014066479A1
|
|
Pichia pastoris strains for producing predominantly homogeneous glycan structure
|
|
WO2013036756A1
|
|
Viable gram negative bacteria with reduced proteolytic activity lacking outer membrane agonists of tlr4/md-2
|
|
WO2011113003A1
|
|
Viable gram negative bacteria lacking outer membrane agonists of tlr4/md-2
|
|
EP2533811A2
|
|
Multimeric proteins comprising immunoglobulin constant domains
|
|
WO2010135678A1
|
|
Nucleic acids of pichia pastoris and use thereof for recombinant production of proteins
|
|
JP2004224793A
|
|
Method of treating endometriosis
|
|
EP1558137A2
|
|
Functional mri agents for cancer imaging
|
|
AU2003243436A8
|
|
Reconstituted polypeptides
|
|
US6825347B2
|
|
Uronium and immonium salts for peptide coupling
|
|
AU2002305535A1
|
|
Nucleic and molecule associated with prostate cancer and melanoma immunodetection and immunotherapy
|
|
WO0226258A2
|
|
Treatment of immune-mediated diseases by oral administration of plasma fractions
|
|
EP1486205A1
|
|
Use of anticonvulsant aminoacids for the treatment of migraine
|
|
AU8299701A
|
|
Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
|
|
US7030099B2
|
|
Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells
|
|
WO0204523A2
|
|
Artificial antibody polypeptides
|
|
US6770261B2
|
|
Magnetic resonance imaging agents for the detection of physiological agents
|
|
AU5957501A
|
|
Magnetic resonance imaging agents for the delivery of therapeutic agents
|
|
CA2406288A1
|
|
Diagnostic assay for endometriosis
|
|
WO0181922A2
|
|
Diagnostic assay for endometriosis
|
|
US2001006619A1
|
|
Compounds for cancer imaging and therapy
|
